Societal Impact Analysis of Introducing Elexacaftor Tezacaftor Ivacaftor (ELX TEZ IVA) in the Management of People With Cystic Fibrosis in Germany: A Paid and Unpaid Work Productivity Approach
Author(s)
Conor Daly, MSc1, Foteini Tsotra, MSc2, Gabriel Ghizzi Pedra, PhD1, Malina Müller, PhD3, Gabriela Vega-Hernandez, BSc, MSc1.
1Vertex Pharmaceuticals, Inc., Boston, MA, USA, 2WifOR Institute, Athens, Greece, 3WifOR Institute, Darmstadt, Germany.
1Vertex Pharmaceuticals, Inc., Boston, MA, USA, 2WifOR Institute, Athens, Greece, 3WifOR Institute, Darmstadt, Germany.
OBJECTIVES: Clinical studies of ELX/TEZ/IVA have demonstrated unprecedented benefits for people with cystic fibrosis (pwCF), however, the societal implications resulting from enhanced health outcomes have not been quantified. The societal impact of ELX/TEZ/IVA in German pwCF aged ≥6 with at least one F508del mutation was estimated using the WifOR Institute approach, focusing on work productivity in monetary terms.
METHODS: The societal impact was estimated by monetizing the benefits of reduced morbidity and mortality in pwCF treated with ELX/TEZ/IVA, based on their ability to complete both paid and unpaid work. Additional aspects of socioeconomic value (e.g. community well-being, tax contribution etc.) are not covered due to data limitations. Direct medical costs are out of scope. An individual patient-level simulation model derived disability adjusted life years (DALY’s) for ELX/TEZ/IVA versus standard of care (SoC) treated pwCF. DALY’s were calculated by combining mortality, years of life lost (YLL’s) and morbidity, years lived with disability (YLD’s) based on age of retirement for paid work and normal life expectancy for unpaid work. Averted DALY’s i.e, avoided DALY’s, were translated into avoided productivity losses, which were monetized using the gross value-added metric.
RESULTS: ELX/TEZ/IVA treated pwCF were projected to live 70.9 years, versus 39.1 years with SoC. Patients on SoC versus general population were projected to endure productivity losses of €2.8 million (mln) over a lifetime (€1.8 mln attributed to unpaid work, €1mln for paid work). PwCF on ELX/TEZ/IVA were projected to have a reduction in DALY’s versus SoC, resulting in 17.8 averted DALY’s for paid work and 22.0 for unpaid work, and a mean per pwCF improvement in productivity of €1.4mln over a lifetime.
CONCLUSIONS: This analysis demonstrates the positive impact of ELX/TEZ/IVA on work productivity in Germany. Further research is recommended to estimate additional aspects of societal impact of ELX/TEZ/IVA and next generation CFTRms.
METHODS: The societal impact was estimated by monetizing the benefits of reduced morbidity and mortality in pwCF treated with ELX/TEZ/IVA, based on their ability to complete both paid and unpaid work. Additional aspects of socioeconomic value (e.g. community well-being, tax contribution etc.) are not covered due to data limitations. Direct medical costs are out of scope. An individual patient-level simulation model derived disability adjusted life years (DALY’s) for ELX/TEZ/IVA versus standard of care (SoC) treated pwCF. DALY’s were calculated by combining mortality, years of life lost (YLL’s) and morbidity, years lived with disability (YLD’s) based on age of retirement for paid work and normal life expectancy for unpaid work. Averted DALY’s i.e, avoided DALY’s, were translated into avoided productivity losses, which were monetized using the gross value-added metric.
RESULTS: ELX/TEZ/IVA treated pwCF were projected to live 70.9 years, versus 39.1 years with SoC. Patients on SoC versus general population were projected to endure productivity losses of €2.8 million (mln) over a lifetime (€1.8 mln attributed to unpaid work, €1mln for paid work). PwCF on ELX/TEZ/IVA were projected to have a reduction in DALY’s versus SoC, resulting in 17.8 averted DALY’s for paid work and 22.0 for unpaid work, and a mean per pwCF improvement in productivity of €1.4mln over a lifetime.
CONCLUSIONS: This analysis demonstrates the positive impact of ELX/TEZ/IVA on work productivity in Germany. Further research is recommended to estimate additional aspects of societal impact of ELX/TEZ/IVA and next generation CFTRms.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE663
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
Rare & Orphan Diseases, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)